Importance of early recognition of heterozygous familial hypercholesterolaemia

Current Opinion in Lipidology

Volumn 26, Issue 4, 2015, Pages 298-303

  Ryan, Aidan ^a   Byrne, Christopher D ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Age of treatment commencement; genetic variants; screening

Indexed keywords

EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

CARDIOVASCULAR RISK; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC VARIABILITY; HETEROZYGOSITY; HISTORY; HUMAN; LOSS OF FUNCTION MUTATION; MASS SCREENING; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; EARLY DIAGNOSIS; GENETIC VARIATION; GENETICS; HETEROZYGOTE; HYPERLIPOPROTEINEMIA TYPE II; RISK;

EARLY DIAGNOSIS; GENETIC VARIATION; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MASS SCREENING; RISK;

EID: 84941370076     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000196     Document Type: Review

References (44)

1. Goldstein JL, Brown MS. The LDL receptor locus and the genetics of familial hypercholesterolemia. Annu Rev Genet 1979; 13:259-289.
2. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34:3478-3490a.
3. Mundal L, Sarancic M, Ose L, et al. Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010. J Am Heart Assoc 2014; 3:e001236.
4. Brautbar A, Leary E, Rasmussen K, et al. Genetics of familial hypercholesterolemia. Curr Atheroscler Rep 2015; 17:491.
5. University College London Low Density Lipoprotein Familial Hypercholesterolemia Database. http://www.ucl.ac.uk/ldlr/LOVDv.1.1.0/index.php?select-db=LDLR. [Accessed on 17 February 2015].
6. Myant NB, Forbes SA, Day IN, Gallagher J. Estimation of the age of the ancesteral arginine3500 > glutamine mutation in human apoB-100. Genomics 1997; 45:78-87.
7. Rodriguez F, Knowles JW. PCSK9 inhibition: current concepts and lessons from human genetics. Curr Atheroscler Rep 2015; 17:487.
8. Maglio C, Mancina RM, Motta BM, et al. Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing. J Intern Med 2014; 276:396-403.
9. Benito-Vicente A, Alves AC, Etxebarria A, et al. The importance of an integrated analysis of clinical, molecular, and functional data for the genetic diagnosis of familial hypercholesterolemia. Genet Med 2015; Mar 5.[Epub ahead of print]
10. Heath KE, Gudnason V, Humphries SE, et al. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-Coa reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1999; 143:41-54.
11. Futema M, Whitall RA, Kiley A, et al. Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic. Atherosclerosis 2013; 229:161-168.
12. Taylor A, Wang D, Patel K, et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet 2010; 77:572-580.
13. Lombardi MP, Redeker EJ, van Gent DH, et al. Molecular genetic testing for familial hypercholesterolemia in the Netherlands: a stepwise screening strategy enhances the mutation detection rate. Genet Test 2006; 10:77-84.
14. Hooper AJ, Nguyen LT, Burnett JR, et al. Genetic analysis of familial hypercholesterolaemia in Western Australia. Atherosclerosis 2012; 224:430-434.
15. Choumerianou DM, Dedoussis GV. Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background. Clin Chem Lab Med 2005; 43:793-801.
16. Etxebarria A, Benito-Vicente A, Palacios L, et al. Functional characterization and classification of frequent low-density lipoprotein receptor variants. Hum Mutat 2015; 36:129-141.
17. Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of Familial Hypercholesterolaemia in UK patients: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006; 43:943-949.
18. Futema M, Shah S, Cooper JA, et al. Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries. Clin Chem 2015; 61:231-238.
19. WHO-Human Genetics, DoNDP, Familial Hypercholesterolaemia-Report of a second WHO consultation, WHO 1999, Geneva.
20. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991; 303:893-896.
21. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72:171-176.
22. Harada-Shiba M, Arai H, Oikawa S, et al. Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 2012; 19:1019-1026.
23. Futema M, Kumari M, Boustred C, et al. Would raising the total cholesterol diagnostic cut-off from 7.5 mmol/L to 9.3 mmol/L improve detection rate of patients with monogenic familial hypercholesterolaemia? Atherosclerosis 2015; 239:295-298.
24. Nherera L, Marks D, Minhas R, et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011; 97:1175-1181.
25. Pears R, Griffin M, Watson M, et al. The reduced cost of providing a nationally recognised service for familial hypercholesterolaemia. Open Heart 2014; 1:e000015.
26. Ademi Z, Watts GF, Juniper A, et al. A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol 2013; 167:2391-2396.
27. Wierzbicki AS, Humphries SE, Minhas R; Guideline Development Group. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 2008; 337:a1095. [complete guideline in website (http://www.nice.org.uk/nicemedia/pdf/CG071NICEGuideline.pdf)]
28. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Pediatrics 2011; 128 (Suppl 5):S213-S256.
29. Descamps OS, Tenoutasse S, Stephenne X, et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 2011; 218:272-280.
30. Kusters DM, Wiegman A, Kastelein JJ, et al. Carotid intima-media thickness in children with familial hypercholesterolemia. Circ Res 2014; 114:307-310.
31. Avis HJ, Kusters DM, Vissers MN, et al. Follow-up of children diagnosed with familial hypercholesterolemia in a national genetic screening program. J Pediatr 2012; 161:99-103.
32. Malhotra A, Shafiq N, Arora A, et al. Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia. Cochrane Database Syst Rev 2014; 6:CD001918.
33. Rabar S, Harker M, O'Flynn N, et al. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ 2014; 349:g4356.
34. Smith SC Jr, Grundy SM. 2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. J Am Coll Cardiol 2014; 64:601-612;
35. Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2014; 7:CD006401.
36. Starr B, Hadfield SG, Hutten BA, et al. Development of sensitive and specific age-and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med 2008; 46:791-803.
37. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358:1431-1443.
38. Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin 2011; 27:1191-1210.
39. Santos RD, Maranhao RC. What is new in familial hypercholesterolemia? Curr Opin Lipidol 2014; 25:183-188.
40. Chapman MJ, Laplaud PM, Luc G, et al. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res 1988; 29:442-458.
41. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascularevents among patients treated with statins: a meta-analysis. JAMA 2012; 307:1302-1309.
42. Alonso R, Andres E, Mata N, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 2014; 63:1982-1989.
43. Lambert G, Petrides F, Chatelais M, et al. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects. J Am Coll Cardiol 2014; 63:2365-2373.
44. Talmud PJ, Shah S, Whittall R. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013; 381:1293-1301.